ArriVent BioPharma Bolsters Board with Biopharmaceutical Expert Dr. John Hohneker

ArriVent BioPharma

NEWTON SQUARE, PA — ArriVent BioPharma, Inc. announced the appointment of Dr. John Hohneker to its Board of Directors. With over three decades of experience in leading biopharmaceutical ventures and a notable track record in drug development, Dr. Hohneker’s addition promises to inject valuable expertise into ArriVent’s efforts to address the critical unmet needs of cancer patients.

Dr. Hohneker’s extensive background includes pivotal roles in both public and private sectors of the healthcare industry. Currently serving on the Boards of Carisma Therapeutics, Inc. and Curis, Inc., as well as privately held companies Sonata Therapeutics and Trishula Therapeutics, his breadth of experience spans across medical affairs, drug development, and the successful launch of market-differentiating medical treatments.

Bing Yao, Chairman and CEO of ArriVent, expressed enthusiasm about the appointment, stating, “We are excited to welcome Dr. Hohneker to our Board of Directors and look forward to his partnership as we work to advance our pipeline, including our lead candidate firmonertinib, and address the unmet needs of cancer patients.” Yao emphasized Dr. Hohneker’s substantial experience in medical affairs and drug development as assets that will contribute to the company’s ongoing projects and future successes.

Expressing his eagerness to contribute to ArriVent’s mission, Dr. Hohneker shared, “I am thrilled to join the ArriVent Board of Directors, not only due to the company’s strong pipeline momentum, but because of the team’s passion for providing patients with potentially transformative medicines.” His commitment to fulfilling the unmet needs of patients aligns with ArriVent’s vision, marking the beginning of a partnership poised to make significant impacts within the oncology space.

READ:  EnerSys Announces Board Retirements and New Director Nominees

Dr. Hohneker’s previous leadership roles, including his time as President and CEO of Anokion SA and President of Research and Development at Forma Therapeutics, Inc., have seen him guide companies through pivotal transitions from discovery to clinical stages. His tenure at Novartis AG as Senior Vice President and Global Head of Development for Immunology and Dermatology is particularly notable for his involvement in the development, approval, and commercialization of key products.

With a solid foundation in chemistry from Gettysburg College and a medical degree from the University of Medicine and Dentistry of New Jersey at Rutgers Medical School, Dr. Hohneker’s scientific and medical acumen are set to be invaluable resources for ArriVent as it navigates the complexities of oncology drug development.

his addition to ArriVent BioPharma’s Board of Directors is a clear signal of the company’s pursuit of excellence in developing and delivering innovative treatments to cancer patients worldwide, demonstrating a proactive approach in shaping the future of oncology treatment.

For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and Microsoft Start.